IBM Reboots Drug Discover - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

IBM Reboots Drug Discover
Can the semiconductor industry help Big Pharma develop therapies?


Pharmaceutical Technology
Volume 35, Issue 5, pp. 14


Erik Greb
Despite the adoption of new research strategies, the pharmaceutical industry's pipelines are slow to grow. Perhaps other industries will take up the challenge of developing new drugs.

It's already happening at IBM, where researchers have unveiled a biodegradable nanoparticle that targets and destroys antibiotic-resistant bacteria, such as Staphylococcus aureus. The nanoparticle's specific electrical charge draws it to an opposite charge on the surface of the bacteria. When it finds its target, the nanoparticle pokes holes in the bacterial membrane and empties out the bacteria, IBM researcher James Hedrick told The Wall Street Journal. By destroying the bacteria, the nanoparticle may prevent them from developing resistance.

The semiconductor industry has embraced many techniques (e.g., outsourcing, supply-chain management, and robotic technology) that drugmakers eventually adopted for their own purposes. IBM's development strikes me as another example of synergies that can be gained across seemingly disparate industries.

Finding the next blockbuster may be much more difficult now than it was in the past. But even if drug candidates are fewer, IBM's nanoparticle shows that technological innovations are increasing. If small- and large-molecule firms keep their minds and eyes open, they might come up with exciting new modes of action or methods of drug delivery. Maybe current challenges—and good examples—will stimulate drugmakers' ingenuity.

Erik Greb is an assistant editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here